PDS Biotechnology Corp — Form 8-K
Filed August 14, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 42/100
What the filing says
PDS Biotechnology amended its Certificate of Incorporation on August 10, 2026, increasing total authorized shares from an unstated prior level to 305M (300M common at $0.00033 par, 5M preferred at $0.00033 par). The amendment was approved by stockholders at the Annual Meeting and became effective upon filing. No specific prior authorization level or reason for the increase is disclosed in this document.
Why this rating
Share authorization increase is routine capital structure housekeeping. Without disclosure of dilution timing/amount or use of proceeds, impact is speculative. Common for biotech to maintain authorization cushion.
See more from August 14, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.